CoChat

Ambroxol for neuropathic pain: hiding in plain sight?

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Abstract

Ambroxol is a multifaceted drug with primarily mucoactive and secretolytic actions, along with anti-inflammatory, antioxidant, and local anaesthetic properties. It has a long history of use in the treatment of respiratory tract diseases and has shown to be efficacious in relieving sore throat. In more recent years, ambroxol has gained interest for its potential usefulness in treating neuropathic pain. Research into this area has been slow, despite clear preclinical evidence to support its primary analgesic mechanism of action—blockade of voltage-gated sodium (Na v) channels in sensory neurons. Ambroxol is a commercially available inhibitor of Na v 1.8, a crucial player in the pathophysiology of neuropathic pain, and Na v 1.7, a particularly exciting target for the treatment of chronic pain. In this review, we discuss the analgesic mechanisms of action of ambroxol, as well as proposed synergistic properties, followed by the preclinical and clinical results of its use in the treatment of persistent pain and neuropathic pain symptoms, including trigeminal neuralgia, fibromyalgia, and complex regional pain syndrome. With its well-established safety profile, extensive preclinical and clinical drug data, and early evidence of clinical effectiveness, ambroxol is an old drug worthy of further investigation for repurposing. As a patent-expired drug, a push is needed to progress the drug to clinical trials for neuropathic pain. We encourage the pharmaceutical industry to look at patented drug formulations and take an active role in bringing an optimized version for neuropathic pain to market.

Overview

Integrity signals

Registry

Crossref · 10.1097/j.pain.0000000000002693

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 84 references

Research works printed but not linked: 4

  1. Fischer, 2002, Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo-controlled trials regarding the local anaesthetic properties, Arzneimittelforschung, 52, 256
  2. Klier, 1977, The local anesthetic effect of NA872-containing eyedrops [in German], Med Monatsschr, 31, 575
  3. Renovanz, 1975, Results of some clinical-pharmacological studies on ambroxol (NA 872) [in German], Arzneimittelforschung, 25, 646
  4. Schutz, 2002, Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept, Arzneimittelforschung, 52, 194

Cited by

See all 22

Metadata

Authors
Russo, M. A., Baron, R., Dickenson, A. H., Kern, K.-U., & Santarelli, D. M.
Affiliations
  • Hunter Pain Specialists, Broadmeadow, NSW, Australia
  • University Hospital Schleswig-Holstein (DE)
  • University College London (GB)
  • Institute for Pain Medicine/Pain Practice Wiesbaden, Wiesbaden, Germany
  • Genesis Research Services, Broadmeadow, NSW, Australia
Corresponding author
Russo, Marc A.
Venue
Pain
Published
2022-05-17
Volume
164
Issue
1
Pages
3-13
ISSN
  • 0304-3959 (ISSN-L)
  • 1872-6623
OpenAlex
W4280593627
Cited by
20
References
83
Citations by year
2026: 5 · 2025: 7 · 2024: 6 · 2023: 2
FWCI
0.52
Type
journal article
Language
en
Open access
closed
Locations
  • Pain (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
Keywords
ambroxol, neuropathic pain, voltage-gated sodium channels, Nav1.8, Nav1.7, analgesic mechanism, drug repurposing, trigeminal neuralgia, fibromyalgia, complex regional pain syndrome, chronic pain, sensory neurons, mucoactive agents
MeSH terms
Ambroxol, Analgesics, Anesthetics, Local, Humans, Neuralgia, Pain Measurement

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ambroxol for neuropathic pain: hiding in plain sight? https://app.cochat.ai/papers/10.1097/j.pain.0000000000002693
The paper
Russo, M. A., Baron, R., Dickenson, A. H., Kern, K.-U., & Santarelli, D. M. (2023). Ambroxol for neuropathic pain: hiding in plain sight? Pain. https://doi.org/10.1097/j.pain.0000000000002693

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.